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Introduction: Current follow‐up arrangements for breast cancer do not optimally 
meet the needs of individual patients. We therefore reviewed the evidence on pref‐
erences	and	patient	 involvement	 in	decisions	about	breast	cancer	follow‐up	to	ex‐
plore the potential for personalised care.
Methods: Studies	published	between	2008	and	2017	were	extracted	from	MEDLINE,	
PsycINFO	and	EMBASE.	We	then	identified	decision	categories	related	to	content	
and form of follow‐up. Criteria for preference sensitiveness and patient involvement 
were	compiled	and	applied	to	determine	the	extent	to	which	decisions	were	sensitive	
to patient preferences and patients were involved.
Results: Forty‐one	 studies	 were	 included	 in	 the	 full‐text	 analysis.	 Four	 decision	
categories were identified: “surveillance for recurrent/secondary breast cancer; 
consultations for physical and psychosocial effects; recurrence‐risk reduction by 
anti‐hormonal treatment; and improving quality of life after breast cancer.” There 
was	little	evidence	that	physicians	treated	decisions	about	anti‐hormonal	treatment,	
menopausal	 symptoms,	 and	 follow‐up	consultations	as	 sensitive	 to	patient	prefer‐
ences. Decisions about breast reconstruction were considered as very sensitive to 
patient	preferences,	and	patients	were	usually	involved.
Conclusion: Patients are currently not involved in all decisions that affect them dur‐
ing	follow‐up,	indicating	a	need	for	improvements.	Personalised	follow‐up	care	could	
improve resource allocation and the value of care for patients.
K E Y W O R D S
breast	neoplasms,	follow‐up	care,	personalised	health	care,	scoping	review,	shared	decision‐
making,	survivorship
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1  | BACKGROUND









et	 al.,	 2015).	 Schemes	 for	 detecting	 recurrences	 often	 comprise	
annual	 physical	 and	mammographic	 examinations	 for	 at	 least	 five	
years,	depending	on	 the	patient's	age,	genetic	predisposition	and/
or tumour characteristics. Consultations that seek to detect physical 
and psychosocial effects are often linked to the visits for recurrence 
detection and are most frequently planned during the first year of 
follow‐up	(IKNL,	2012;	Senkus	et	al.,	2015).
At	present,	 arrangements	 for	 follow‐up	 suboptimally	meet	 the	
needs	 of	 patients	with	 breast	 cancer,	 and	 there	 is	 concurrently	 a	
growing demand for personalised care planning within cancer follow‐
up	care	(DH	Macmillan	Cancer	Support	&	NHS	Improvement,	2010;	
Donnelly,	Hiller,	Bathers,	Bowden,	&	Coleman,	2007;	Montgomery,	
Krupa,	 &	 Cooke,	 2007;	 Zorginstituut	Nederland,	 2016).	 Such	 per‐
sonalised	follow‐up	care	could	be	based	on	the	patient's	individual	




al.,	 2015).	 Moreover,	 cancer	 survivors	 might	 experience	 very	 dif‐
ferent	psychosocial	consequences	after	the	disease	and	treatment,	
including	 fear	 of	 recurrence,	 sleeping	 difficulties,	 cognitive	 issues,	
fatigue	 and	 sexual	 issues	 (Ewertz	 &	 Jensen,	 2011).	 Each	 of	 these	
effects requires a personalised follow‐up strategy. Patient prefer‐
ences about the preferred form and content of the follow‐up care 
have	been	reported	in	previous	studies	(Kimman,	Dellaert,	Boersma,	
Lambin,	&	Dirksen,	2010;	Murchie	et	al.,	2016).
Since	 the	 advent	 of	 value‐based	 health	 care,	 there	 have	 been	
ongoing efforts to improve care quality by adding value throughout 
an	 individual	 patient's	 journey	 from	 diagnosis,	 through	 treatment,	
and	to	follow‐up	care	(Porter	&	Teisberg,	2007).	A	way	to	meet	this	
goal of personalised care is to include patients and their preferences 
in	 the	 decision‐making	 process.	 For	 example,	 in	 the	 shared	 deci‐
sion‐making	 (SDM)	 process,	 decisions	 are	 based	 on	 both	 the	 best	
available	 (medical)	 evidence	 and	 the	 patients’	 needs	 and	 values.	
Preference‐sensitive care involves making treatment decisions with 
significant	trade‐offs	that	should	reflect	a	patient's	personal	values	
and	preferences.	Besides,	only	when	patients	have	enough	informa‐





In	 the	 present	 study,	 we	 hypothesised	 that	 decisions	 about	
breast	 cancer	 follow‐up	 are	 sensitive	 to	 patient	 preferences,	 and	




about breast cancer follow‐up care.
2  | METHODS




during follow‐up about content or form of follow‐up care for breast 
cancer	survivors?”	(b)	“to	what	extent	are	these	decisions	sensitive	
to	 patient	 preferences?”	 and	 (c)	 “to	what	 extent	 and	 how	 are	 pa‐
tients with breast cancer involved in making these decisions?” The 
literature	was	searched	separately	for	each	question,	between	18th	
July	and	25th	September	2017,	in	the	MEDLINE	(accessed	through	
PubMed),	 PsycINFO	 (accessed	 through	 Ovid)	 and	 EMBASE	 da‐
tabases	 (Table	1).	We	 included	any	 study	 that	discussed	decisions	
made	 or	 interventions	 applied	 during	 follow‐up	 for	 breast	 cancer,	
provided	it	was	written	in	English	and	published	in	the	last	10	years	
(2008–2017).	 The	 time	 restriction	was	 set	 because	 breast	 cancer	
care and treatment have changed significantly over previous dec‐
ades. The follow‐up period was defined as the time period after sur‐
gery for breast cancer.




describe	 the	 patients'	 roles	 in	 decision‐making.	 Studies	were	 also	




was used to manage all search results.
2.2 | Quality assessment
The quality of the included studies was assessed by the Critical 
Appraisal	Skills	Programme	checklist,	comprising	criteria	for	quali‐
tative	 studies,	 randomised	 controlled	 trails,	 cohort	 studies	 and	
systematic reviews. Criteria could be scored with a positive or 
negative response; when criteria were not applicable or unknown/
unable	 to	be	assessed,	 this	was	 recorded	as	well	 ().	First,	we	de‐
termined	the	study	design	for	each	 included	study,	provided	this	
was	not	already	described	in	the	study's	method	section.	Studies	
were deemed of sufficient quality when half or more of the criteria 
     |  3 of 17de LIGT eT aL.
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content or form of follow‐up care delivered to breast cancer patients. 
Second,	criteria	were	compiled	to	determine	whether	decisions	were	
sensitive to patient preferences and whether patients were involved in 
making	the	decisions.	Third,	these	criteria,	in	turn,	were	used	to	assess	




ered preference‐sensitive if the following criteria were met:
0.	There	were	multiple	options	available	(PS0);	and









the actions required for the preferred option had high impact on 
the	patient's	lifestyle	(PS5).
Criteria	 for	 the	extent	of	patient	 involvement	 (SDM1‐7)	were	based	
on	the	conditions	set	by	Légaré	et	al.	(2008)	and	the	components	de‐
scribed	by	Coulter	and	Collins	(2011):
1.	 The	 decision	 was	 preference‐sensitive	 (SDM1);	 and
2.	 There	was	sufficient	time	to	make	a	decision	(SDM2);	and/or
3. The patient was capable and sufficiently informed to make a deci‐
sion	(SDM3);	and/or
4.	 There	was	 a	 belief	 that	 SDM	would	 lead	 to	better	 patient	 out‐
comes	(SDM4);	and/or











Within	 the	 screened	 records,	 “follow‐up” often referred to the 
study	 design	 rather	 than	 the	 post‐treatment	 period,	 and	 “prefer‐
ence‐sensitive”	was	 used	 little	 or	 infrequently,	 only	 appearing	 as	 a	
F I G U R E  1  PRISMA	flow	chart	of	
study inclusion. *Three literature searches 




by cross‐checking between the searches. 
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key word in 21 records. Studies also generally described gaps in 











ments and semi‐structured/directed/open‐ended interviews. The 
survey‐based studies included larger samples (n	 =	 5–41),	whereas	
the interview‐based studies included smaller groups (n	 =	 5–41).	
Less	common	methods	included	studies	of	electronic	health	records	
(n	=	1)	and	internet	fora	(n	=	1).	Randomised	Controlled	Trials	(RCT)	
designs were used for studies about lifestyle interventions (n	=	2)	
and	SDM‐related	tools	about	breast	reconstruction	(n	=	3).
Table 2 summarises the preference‐sensitive aspects (criterion 
PS)	and	aspects	of	patient	involvement	(criterion	SDM)	for	each	de‐
cision about the content or form of follow‐up care. Decisions were 
classified	into	those	concerning	(a)	“surveillance	for	recurrent	or	sec‐
ondary	 breast	 cancer”;	 (b)	 “consultations	 for	 physical	 and	 psycho‐
social	(late)	effects”;	(c)	“recurrence‐risk	reduction	by	anti‐hormonal	
treatment”;	 and	 (d)	 “improving	 quality	 of	 life	 after	 breast	 cancer.”	
Results are described in more detail below. Table S1 summarises the 
included studies.
3.1 | Surveillance for recurrent or secondary 
breast cancer
Follow‐up	aims	to	detect	recurrent	disease	or	new	associated	ma‐
lignancies at an early stage through surveillance imaging (mam‐
mography	and/or	MRI)	and	physical	examination	(Grunfeld	et	al.,	
2005;	IKNL,	2012;	Runowicz	et	al.,	2016;	Senkus	et	al.,	2015).	Two	
included studies discussed decisions about the form and frequency 
of surveillance imaging	 (PS0)	 (Brandzel	 et	 al.,	 2017;	 Klaassen,	
Dirksen,	Boersma,	&	Hoving,	2017).	Klaassen	et	al.	assessed	 the	
needs of Dutch patients and physicians with regard to an after‐
care	decision	aid.	Brandzel	et	al.	 then	described	the	experiences	
and preferences for breast imaging among breast cancer survi‐
vors in the United States. The main form of surveillance tended 
to	 be	mammography,	 though	 some	 also	 received	MRI;	 however,	
the authors did not specify who received what type of surveil‐
lance imaging or the reasons for the differences. If their breast 
cancer	initially	was	missed	on	mammography,	patients	sometimes	
lost trust in this method and preferred other imaging modalities. 
Furthermore,	many	patients	received	surveillance	mammography	
more often than the recommended annual frequency without 
clinical	 indication	 (Brandzel	 et	 al.,	 2017).	 Patients	 preferred	 this	
higher frequency because it reassured them about the absence of 
recurrences	(Brandzel	et	al.,	2017;	Klaassen	et	al.,	2017).	However,	
breast	 imaging	 also	 caused	 anxiety	 and	was	 considered	 uncom‐
fortable	 for	 many	 patients	 (Brandzel	 et	 al.,	 2017),	 suggesting	
scope for a trade‐off between burdens and benefits of surveil‐
lance	 imaging	 (PS1).	 Surveillance	preferences	were	also	affected	
by	financial	costs	and	insurance	coverage	(Brandzel	et	al.,	2017),	
and	therefore,	the	patient's	willingness	to	bear	these	costs	(PS5).
Little	 evidence	 was	 found	 for	 patient	 involvement	 in	 surveil‐
lance‐related	decisions.	Brandzel	 et	 al.	 found	 that	physicians	 typi‐
cally determined the imaging type and frequency of surveillance 
(SDM5),	despite	the	opposing	preferences	and	trade‐offs	expressed	
by	patients.	The	patient's	understanding	of	the	goal	of	surveillance	
could be improved here: patients felt confused about the options 
for the type of surveillance imaging and frequency of surveillance 
imaging,	and	expressed	a	need	for	information	about	the	transition	
from	treatment	to	surveillance	care	(SDM3).	The	aftercare	decision	
aid produced by Klaassen et al. provides an overview of follow‐up 
options	(SDM7)	and	could	reduce	information	needs	before	initiating	
follow‐up. Surveillance length was not discussed in the literature.
Hereditary testing is most often performed during breast cancer 
diagnosis	 and	may	be	 less	 relevant	during	 follow‐up	 (IKNL,	2012).	
However,	Rini	et	al.	 (2009)	described	hereditary	 testing	 in	women	
with a history of breast cancer. Hereditary testing leads to informa‐
tion about the risk of secondary breast cancer and/or risk of breast 
cancer or ovarian cancer in family members. This can affect surveil‐
lance	schemes	or	preventative	options,	such	as	contralateral	prophy‐
lactic	mastectomy	(PS0).
3.2 | Consultations for physical and psychosocial 
(late) effects
The second goal of follow‐up is informing and counselling patients 
about	 the	 physical	 and	 psychosocial	 (late)	 effects	 of	 treatment	
(Grunfeld	 et	 al.,	 2005;	 IKNL,	2012;	Runowicz	 et	 al.,	 2016;	 Senkus	
et	al.,	2015).	Two	studies	described	decision‐making	regarding	the	
form, frequency and length of follow‐up consultations within follow‐up 
care	 (PS0).	 Patients	 preferred	more	 personal	 attention	 from	 their	




Hudson et al. had received follow‐up care from a cancer specialist 
within	 the	previous	year,	even	though	the	time	since	their	 last	ac‐
tive cancer treatment ranged from three to seventeen years; how‐
ever,	decisions	about	length	were	not	discussed	further	(Hudson	et	
al.,	 2012).	 Regarding	 the	 form	 of	 consultations,	 patients	 preferred	
consultations	 by	 a	 breast	 cancer	 specialist,	 possibly	 alternated	
with	nurse	consultations	(PS1)	(Klaassen	et	al.,	2017).	Regardless	of	
these	preferences,	patients	were	 rarely	offered	options	about	 the	
frequency,	 form	 or	 length	 of	 consultations,	 indicating	 low	 patient	
involvement.
By	 contrast,	 most	 physicians	 stated	 that	 SDM	 was	 common	
practice	in	their	healthcare	facilities	and	in	their	own	work,	and	re‐
ported	 that	 using	 SDM	made	 the	patients	 feel	 positively	 involved	



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































12 of 17  |     de LIGT eT aL.
in	 decisions	 related	 to	 follow‐up	 (SDM5)	 (Klaassen	 et	 al.,	 2017).	




3.3 | Recurrence‐risk reduction by anti‐
hormonal treatment
Seven studies described treatment decisions about anti‐hormo‐
nal therapy	 (Benedict,	 Thom,	 Teplinsky,	 Carleton,	 &	 Kelvin,	 2017;	
Bluethmann	 et	 al.,	 2017;	 Brauer,	 Ganz,	 &	 Pieters,	 2016;	 Cahir	 et	
al.,	2015;	Engelhardt	et	al.,	2016;	Hershman	et	al.,	2016;	Neugut	et	
al.,	 2012).	 This	 consisted	 of	 tamoxifen	 or	 aromatase	 inhibitor	 use	
to	 increase	 locoregional	 tumour	 control	 and	 survival,	 given	 for	 a	
minimum	of	five	consecutive	years,	and	continuing	during	follow‐up	
(IKNL,	2012).	Respectively,	there	were	two	and	five	studies	on	deci‐




as	 a	 preference‐sensitive	 decision:	 one	 study	 described	 that	 96%	
of	patients	were	steered	 towards	anti‐hormonal	 therapy,	 irrespec‐
tive	 of	 the	 expected	 benefit	 (Engelhardt	 et	 al.,	 2016);	 in	 another	
study,	patients	 felt	obliged	 to	 take	 the	 therapy	 (PS0)	 (Bluethmann	
et	al.,	2017).	However,	 the	decision	about	anti‐hormonal therapy is 
not an one‐off decision: four studies described that the decision to 
adhere to anti‐hormonal therapy leads to patients making an ongo‐
ing risk‐versus‐benefit trade‐off between the risk‐reducing effect of 
treatment	and	the	severity	of	treatment‐induced	side	effects	(PS4)	
(Benedict	et	al.,	2017;	Bluethmann	et	al.,	2017;	Brauer	et	al.,	2016;	
Cahir	 et	 al.,	 2015;	Hershman	 et	 al.,	 2016).	Non‐adherent	 patients	
in two studies felt unable to cope with side effects that severely 
affected	 their	 lives	 (PS5)	 (Bluethmann	 et	 al.,	 2017;	 Brauer	 et	 al.,	
2016).	Three	studies	reported	that	professional	guidance	or	support	
from physicians for managing these side effects could be improved 
(Benedict	et	al.,	2017;	Brauer	et	al.,	2016;	Cahir	et	al.,	2015).	Such	
guidance	is	 important,	because	patients	can	better	persevere	with	
side effects if they have a high belief in their ability to manage and 





Frequently	 reported	 effects	 of	 anti‐hormonal	 therapy	 were	
menopausal	 symptoms	 and	 joint	 pain,	with	 cognitive	 decline	 and	
cardiac	 distress	 also	 occurring,	 but	 less	 frequently	 (Bluethmann	
et	 al.,	 2017).	 Two	 studies	 specifically	 discussed	 the	 identification	
and treatment of treatment‐induced menopausal symptoms	 (PS0)	
(Balneaves	et	al.,	2016;	Sayakhot,	Vincent,	&	Teede,	2012),	such	as	
hot	 flashes,	weight	gain,	 loss	of	 sexuality	and	 increased	osteopo‐
rosis. Symptom treatment was considered a preference‐sensitive 
decision because hormone replacement therapy is the customary 
and	 most	 effective	 option,	 even	 though	 it	 increases	 the	 risk	 of	
recurrence and should be avoided in patients with breast cancer 
(PS4)	(Balneaves	et	al.,	2016;	Sayakhot	et	al.,	2012).	However,	there	
are	 few	 alternatives	 (PS2),	 with	 these	 limited	 to	 various	 lifestyle	
changes,	 pharmaceutical	 options	 and	 complementary	 treatments	
(e.g.,	mind‐body	therapies	and	natural	health	products)	(Balneaves	
et	 al.,	 2016).	 As	 both	 studies	 reported,	 a	 lack	 of	 reliable	 and	 un‐
ambiguous information about these options makes it difficult to 
select	 the	 best	 option	 (PS3).	 Concerning	 this	 dilemma,	 patients	
were	frustrated	by	the	lack	of	conclusive	information,	particularly	
about	complementary	therapies,	and	by	an	inability	to	differentiate	
between	 credible	 and	 non‐credible	 information	 sources	 (SDM3).	
Balneaves	et	al.	suggested	using	an	SDM‐tool	that	could	summarise	




3.4 | Improving quality of life after breast 
cancer treatment
This	topic	was	subdivided	into	three	subtopics.	Sixteen	studies	fo‐
cused on delayed breast reconstruction,	two	on	lifestyle changes,	and	
four on getting pregnant after breast cancer.
Breast	 reconstruction	 yields	 positive	 psychosocial	 effects	
(Causarano	 et	 al..,	 2015;	 Flitcroft	 et	 al.,	 2016;	 Potter,	 Mills,	
Cawthorn,	Wilson,	&	Blazeby,	2013;	Zielinski,	Lorenc‐Podgorska,	&	
Antoszewski,	2015)	and	may	contribute	to	the	patients	well‐being	
after	 breast	 cancer.	 Although	 some,	 if	 not	 most	 decisions	 about	
breast	 reconstruction	 are	made	 before	 surgical	 treatment,	 result‐
ing	 in	 immediate	 breast	 reconstruction,	 some	 patients	 and/or	 cli‐
nicians delay the decision about breast reconstruction until after 
treatment. Patients must then first decide whether to undergo 
delayed	 breast	 reconstruction,	 and	 when	 they	 do,	 decide	 which	
reconstruction	 technique	 should	 be	 used	 (PS0).	 Decisions	 about	
delayed breast reconstruction can remain relevant years after tu‐
mour	surgery	(Alderman	et	al.,	2011;	Sherman	et	al.,	2016)	and	have	
been recognised as highly preference‐sensitive in three studies 
(Causarano	et	al.,	2015;	Lee,	Hultman,	&	Sepucha,	2010;	Ogrodnik,	
Maclennan,	Weaver,	 &	 James,	 2016).	 Furthermore,	 seven	 studies	
indicated that breast reconstruction yields positive psychosocial 
effects	 (Causarano	et	al.,	2015;	Flitcroft	et	al.,	2016;	Potter	et	al.,	
2013;	Zielinski	 et	 al.,	 2015)	 and	 that	 it	 is	 an	 important	option	 for	
patients	who	have	undergone	mastectomy	(Alderman	et	al.,	2011;	
Fasse	et	al.,	2017;	Fu,	Chang,	Chen,	&	Rohde,	2017).	In	three	studies,	
common reasons for opting to delay breast reconstruction rather 
than	 undergoing	 immediate	 breast	 reconstruction	were	 reported,	
and it was concluded that either patients wanted to focus on other 





     |  13 of 17de LIGT eT aL.
et	al.,	2016).	Thus,	apart	from	medical	contraindications,	decisions	
about undergoing breast reconstruction were affected by its timing 













Current patient involvement in decisions about breast recon‐
struction appeared to be high: fifteen studies described elements 
of	patient	 involvement	or	SDM	 (Alderman	et	al.,	2011;	Causarano	
et	al.,	2015;	Fasse	et	al.,	2017;	Flitcroft	et	al.,	2016;	Fu	et	al.,	2017;	










Zielinski	 et	 al.,	 2015)	 and	 eight	 studies	 recommended	 further	 im‐
provement	of	information	provision	(SDM3)	(Alderman	et	al.,	2011;	
Causarano	 et	 al.,	 2015;	 Fu	 et	 al.,	 2017;	 Hamnett	 &	 Subramanian,	
2016;	Heller	et	al.,	2008;	Morrow	et	al.,	2014;	Ogrodnik	et	al.,	2016;	
Potter	 et	 al.,	 2013).	This	 could	be	 addressed	by	using	one	of	 four	
decision	 aids	 that	have	been	developed	 (SDM7)	 (Causarano	et	 al.,	




get pregnant after treatment for breast cancer	 (Benedict	et	al.,	2017;	
Corney	&	Swinglehurst,	2014;	Gorman,	Usita,	Madlensky,	&	Pierce,	
2011;	Hsieh	&	Huang,	2017).	Although	this	decision	may	feel	like	a	
risk,	 there	 is	 consensus	 that	 pregnancy	 following	 breast	 cancer	 is	
safe	(Corney	&	Swinglehurst,	2014).	Nevertheless,	both	patients	and	
physicians	 have	 expressed	 concerns	 about	 the	 potential	 for	 preg‐
nancy to increase recurrence risk in patients with hormone‐sensitive 
breast	 cancer	 (PS4)	 (Corney	&	 Swinglehurst,	 2014;	Gorman	 et	 al.,	
2011;	Hsieh	&	Huang,	2017).	Patients	not	only	felt	under	informed	
(SDM3)	 (Corney	&	 Swinglehurst,	 2014),	 but	 also,	 patients	worried	
whether breast cancer and its treatment would negatively affect the 
health	of	a	future	child	(PS4)	(Corney	&	Swinglehurst,	2014;	Hsieh	
&	Huang,	 2017).	 In	 general,	 there	was	 a	wide	 variety	 in	 the	 level	
of concern about fertility and getting pregnant. The importance of 
family‐building	 depended	 on	 personal	 circumstances,	 values	 and	
expectations	 (Corney	&	 Swinglehurst,	 2014;	 Gorman	 et	 al.,	 2011;	
Hsieh	&	Huang,	2017).	In	a	study	of	Chinese	breast	cancer	survivors,	
social and cultural perceptions about having children were important 
motives	 (PS1)	 (Hsieh	&	Huang,	 2017).	 Although	 all	 three	 included	




patients. Those on anti‐hormonal therapy may therefore have to 
wait	to	the	end	of	the	treatment	period	(i.e.,	5	years),	while	may	be	
accompanied	by	an	age‐related	decline	in	fertility	(PS1).	In	some	pa‐
tients,	oncologists	were	willing	 to	discuss	 the	option	of	a	 reduced	
duration	of	anti‐hormonal	treatment	(Corney	&	Swinglehurst,	2014).	
Another	study	recognised	the	need	to	counsel	patients	about	fam‐
ily‐building	 periodically	 during	 anti‐hormonal	 treatment	 (Benedict	
et	 al.,	 2017).	 Indeed,	 fertility	 counselling	 may	 remain	 important	
throughout follow‐up because treatment‐affected fertility may have 
negative	psychosocial	consequences	(Gorman	et	al.,	2011;	Hsieh	&	
Huang,	2017).
Chemotherapy treatment can also lead to reduced fertility. 
Therefore,	patients	should	have	the	option	to	choose	from	a	range	
of	artificial	 reproductive	 techniques,	 including	ovarian	stimulation,	
and	 oocyte	 or	 embryo	 cryopreservation,	 before	 treatment	 (PS0)	
(Corney	&	Swinglehurst,	2014).	These	decisions	will	also	affect	deci‐
sion‐making	during	follow‐up,	for	instance,	patients	who	have	opted	
for artificial reproductive techniques before treatment will have to 




what to do with the oocytes or embryos.
Quality‐of‐life	improvements	after	cancer	may	be	found	by	im‐




fruit and vegetable intake were based on an individual weighing the 
pros	and	cons	of	making	a	change	(the	so‐called	decisional	balance)	
(PS1).	Carter	et	al.	(2010)	described	the	reasons	for	cancer	patients	
to participate in either of two physical activity programmes (walking 
or	 “dragon	boat”	 rowing)	offered	 in	 their	RCT.	They	 reported	 that	
decisions	were	based	on	physical	 (health	benefits),	 social	 (meeting	
new	 people,	 learning	 new	 skills)	 and	 practical	 (time	 investment,	
scheduling)	considerations,	but	did	not	state	whether	 the	decision	
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in decisions about follow‐up care. We identified many decisions 
that	needed	to	be	made	during	follow‐up,	including	those	related	
to	 surveillance	 imaging,	 follow‐up	 consultations,	 anti‐hormonal	
treatment,	treatment‐induced	menopausal	symptoms	and	lifestyle	
changes.	Moreover,	we	identified	decisions	that	were	made	during	
treatment,	 but	 that	 required	 additional	 decisions	 during	 follow‐
up,	such	as	delayed	breast	reconstruction,	hereditary	testing	and	
pregnancy. The literature revealed that there was a large variety 
in the degree of preference sensitiveness and patient involvement 
with each decision during follow‐up. Decisions about delayed 
breast	 reconstruction,	 for	 instance,	were	among	those	shown	to	
be highly preference‐sensitive and for which many indications 
for	patient	involvement	existed.	Equally,	however,	decisions	were	
identified	for	which	patients	exhibited	preferences,	but	for	which	
they	were	 not	 necessarily	 involved.	 Notably,	 this	 included	 deci‐
sions	about	the	form,	frequency	and	length	of	surveillance	imaging	
and follow‐up consultations. Some decisions were not currently 
regarded as preference‐sensitive with a low recognition of the 
need	 for	 patient	 involvement,	 such	 as	 decisions	 about	 anti‐hor‐




form,	 frequency	 and	 length	 of	 surveillance	 imaging,	 patients	 de‐








evidence‐based recommendations about surveillance schemes and 
imaging	modalities	 (Grunfeld	 et	 al.,	 2005;	 IKNL,	 2012;	 Runowicz	
et	 al.,	 2016;	 Senkus	 et	 al.,	 2015).	We	 suspect	 that	 the	 identified	
preferences	were	primarily	based	on	 the	patient's	need	 for	 reas‐
surance	(Allen,	2002;	Brandzel	et	al.,	2017;	Klaassen	et	al.,	2017),	
and that they may be unaware that more intensive surveillance has 
no	evidence	base	(Rosselli	Del	Turco	et	al.,	1994),	or	that	increased	
exposure	 might	 even	 be	 harmful	 (Grunfeld,	 2009;	 Meyer	 et	 al.,	
2019).	 Efforts	 should	 be	made	 to	 improve	patient	 understanding	
of	 the	 goals	 of	 surveillance	 (Kwast,	 Drossaert,	 &	 Siesling,	 2013),	
specifically at the point of transition from treatment to follow‐
up	 (Brandzel	et	 al.,	 2017;	Schmidt	et	 al.,	 2016).	Furthermore,	 the	
frequency and length of surveillance could be determined by re‐
currence‐risk	 stratification	 (Grunfeld,	 2009),	 based	 on	 data	 from	
nomograms	 or	 risk‐calculators.	 Although	 Rabin	 et	 al.	 (2013)	 re‐
viewed	22	cancer	prognostic	tools,	of	which	8	focussed	on	breast	
cancer,	 patient	 involvement	 with	 these	 tools	 was	 not	 discussed.	
The authors found only limited evidence reporting actual use of 
these in practice.
Issues	also	existed	for	follow‐up	consultations	aimed	at	the	phys‐
ical and psychosocial effects of treatment. The available research 
indicated that patients preferred more frequent consultations than 
was	 recommended,	 that	 these	 should	be	 led	by	 specialised	oncol‐
ogy	providers	(Klaassen	et	al.,	2017),	and	that	these	should	be	pro‐
vided	over	a	longer	period	of	time	(Hudson	et	al.,	2012).	As	literature	






ers	 (Hudson	et	al.,	2012),	 suggesting	 that	 referral	 for	personalised	
care may sometimes be more appropriate than providing general 
oncology‐led	 follow‐up.	 We	 expect	 that	 using	 patient‐reported	
outcome	measures	(PROMs)	would	help	to	identify	patients’	needs	
regarding	specific	 forms	of	care	 (Black,	2013).	PROMs	can	 include	
symptom‐specific	scales	about,	for	 instance,	physical	 impairments,	
sexuality	problems,	psychosocial	problems	and	body	 image	 (Cano,	
Klassen,	 Scott,	 &	 Pusic,	 2013;	Wintner	 et	 al.,	 2016).	 Patients	 and	




Decisions about anti‐hormonal treatment had little recogni‐
tion	 as	 preference‐sensitive	 decisions	 among	 physicians,	 which	 is	
somewhat	consistent	with	the	2015	European	Society	for	Medical	
Oncology	 guideline.	 Although	 this	 guideline	 states	 that	 follow‐up	






et	 al.,	 2015).	 This	 leaves	 patients	 struggling	 to	 cope	with	 difficult	
symptoms	 with	 minimal	 support	 (Brauer	 et	 al.,	 2016).	 Given	 that	
therapy adherence depends on perseverance despite side effects 
(Bluethmann	et	al.,	2017;	Brauer	et	al.,	2016),	 the	needs	and	pref‐









support to ensure treatment compliance and management of side 
effects	 (Cardoso	 et	 al.,	 2012;	 Howard‐Anderson,	 Ganz,	 Bower,	 &	
Stanton,	2012;	Meade	et	al.,	2017).
4.1 | Strengths and limitations
Several limitations should be kept in mind when interpreting the 
results	of	this	study.	 In	the	 interview	and	focus‐group	studies,	the	
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samples	 included	 in	 these	studies	were	small,	which	may	 limit	 the	
generalisability	of	the	data.	However,	all	the	included	studies	were	
rated as valuable in the quality assessment.












sonalisation of follow‐up care may lead to care that is not only 
of	greater	value	for	the	individual	patient,	but	also	to	care	that	is	
more	appropriate	from	a	financial	perspective,	potentially	leading	
to more responsible use of available healthcare services as well. 
The process used when deciding on breast reconstruction may be 
considered	an	example	of	best	practice	for	other	decisions	about	
follow‐up.	 Eight	 studies	 recommended	 improvement	 in	 informa‐
tion	provision	 (Alderman	et	al.,	2011;	Causarano	et	al.,	2015;	Fu	
et	 al.,	 2017;	Hamnett	&	 Subramanian,	 2016;	Heller	 et	 al.,	 2008;	
Morrow	et	al.,	2014;	Ogrodnik	et	al.,	2016;	Potter	et	al.,	2013),	and	
four reported on decision aids to address these information gaps 
(Causarano	et	al.,	2015;	Heller	et	al.,	2008;	Sherman	et	al.,	2016;	
Temple‐Oberle	et	al.,	2014).	Although	patient	involvement	seemed	
to be more straightforward when making elective decisions about 
breast	 reconstruction,	 true	 involvement	 in	 the	 decision‐making	
process requires that patients be given the best available evi‐
dence,	 including	 details	 of	 the	 risks	 and	 benefits	 (Légaré	 et	 al.,	
2008).	When	 the	 evidence	 for	 a	 certain	 decision	 is	 low,	 such	 as	




We identified a variety of decisions that can be made about the 
content or form of follow‐up care for patients with breast cancer. 




patient's	 role	 and	 the	 involvement	 in	 decisions	 where	 their	 input	
is	both	relevant	and	possible.	Further	personalisation	of	 follow‐up	
care may lead to care of greater relevance and value to individual 
patients.
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